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ABSTRACT 
In severe cases of coronavirus disease 2019 (COVID-19), viral pneumonia progresses to 
respiratory failure.  Neutrophil extracellular traps (NETs) are extracellular webs of chromatin, 
microbicidal proteins, and oxidant enzymes that are released by neutrophils to contain 
infections.  However, when not properly regulated, NETs have potential to propagate 
inflammation and microvascular thrombosis—including in the lungs of patients with acute 
respiratory distress syndrome.  While elevated levels of blood neutrophils predict worse 
outcomes in COVID-19, the role of NETs has not been investigated.  We now report that sera 
from patients with COVID-19 (n=50 patients, n=84 samples) have elevated levels of cell-free 
DNA, myeloperoxidase(MPO)-DNA, and citrullinated histone H3 (Cit-H3); the latter two are 
highly specific markers of NETs.  Highlighting the potential clinical relevance of these findings, 
cell-free DNA strongly correlated with acute phase reactants including C-reactive protein, D-
dimer, and lactate dehydrogenase, as well as absolute neutrophil count.  MPO-DNA associated 
with both cell-free DNA and absolute neutrophil count, while Cit-H3 correlated with platelet 
levels.  Importantly, both cell-free DNA and MPO-DNA were higher in hospitalized patients 
receiving mechanical ventilation as compared with hospitalized patients breathing room air.  
Finally, sera from individuals with COVID-19 triggered NET release from control neutrophils in 
vitro.  In summary, these data reveal high levels of NETs in many patients with COVID-19, 
where they may contribute to cytokine release and respiratory failure.  Future studies should 
investigate the predictive power of circulating NETs in longitudinal cohorts, and determine the 
extent to which NETs may be novel therapeutic targets in severe COVID-19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
To date, the coronavirus disease 2019 (COVID-19) pandemic has affected more than two 
million individuals from over 250 countries, and has resulted in unprecedented health, social, 
and economic crises (https://coronavirus.jhu.edu/map.html).  The disease is caused by severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), manifesting with flu-like symptoms 
and a viral pneumonia that progresses to acute respiratory distress syndrome (ARDS) and even 
multi-organ failure in some individuals (1). 
 
Elevated levels of blood neutrophils are an early indicator of SARS-CoV-2 infection, predicting 
severe respiratory disease and worse outcomes (2, 3).  Over the past decade, our group and 
many others have revealed a pathogenic role for neutrophil-derived neutrophil extracellular 
traps (NETs) in various thrombo-inflammatory states including sepsis (4, 5), thrombosis (6-8), 
and respiratory failure (9, 10).  NETs are extracellular webs of DNA, histones, microbicidal 
proteins, and oxidant enzymes that are released by neutrophils to corral infections; however, 
when not properly regulated, NETs have potential to initiate and propagate inflammation and 
thrombosis (11, 12).  Indeed, inhibition of neutrophils and NETs are protective in various models 
of influenza-associated ARDS (13-16).  Although it has yet to be assessed whether NETs 
contribute to the inflammatory storm that leads to respiratory failure in many COVID-19 patients, 
there is emerging evidence to implicate inflammatory cytokines such as interleukin (IL)-1β and 
IL-6 in the COVID-19 milieu (17).  Not surprisingly, NETs are intimately intertwined with both 
cytokines, and especially IL-1β, in many pulmonary and cardiovascular diseases (8, 18-23).   
 
Other pandemic viruses including influenza H1N1, SARS-CoV, and MERS-CoV are associated 
with neutrophilic infiltration at sites of infection and development of ARDS (24, 25).  The acute, 
exudative phase of ARDS is characterized by an exuberant immune response productive of pro-
inflammatory cytokines and chemokines; increased neutrophil infiltration and accumulation in 
the alveoli; and disruption of the alveolar epithelial-capillary barrier (26).  Culturing neutrophils in 
vitro with influenza-infected lung epithelial cells triggers NETosis and augments endothelial 
damage by culture supernatants (13).  Neutrophil-depleted mice demonstrate milder lung 
pathology in response to influenza infection, including lower levels of thrombomodulin, matrix 
metalloproteinases, and MPO in bronchoalveolar lavage fluid (13).  At the same time, influenza-
infected mice are protected by strategies that prevent NETosis including inhibition of superoxide 
dismutase (13) and MPO (13, 27).  In patients with influenza A infection, high levels of NETs 
predict a poor prognosis (28). 
Work to date exploring pathophysiology of COVID-19 has focused especially on macrophages 
and epithelial cells, with little attention paid to neutrophils and their catalysts, checkpoints, and 
effector mechanisms—all of which could add actionable context to our understanding of the 
COVID-19 inflammatory storm.  Here, as a first step toward assessing the role of NETs in 
COVID-19, we sought to measure various markers of NETs in sera of hospitalized patients and 
to determine their relationship to severity of illness. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
Detection of NETs in sera of COVID-19 patients.  Serum samples were obtained from 50 
patients hospitalized with COVID-19 at a large academic hospital (Table 1).  As compared with 
serum samples from 30 healthy controls, the COVID-19 samples showed higher levels of cell-
free DNA (Figure 1A), myeloperoxidase-DNA complexes (MPO-DNA, Figure 1B), and 
citrullinated histone H3 (Cit-H3, Figure 1C).  The latter two markers are generally regarded as 
relatively specific for NET remnants.  While cell-free DNA and MPO-DNA demonstrated a 
significant correlative relationship (Figure 1D), the association between cell-free DNA and Cit-
H3 was not significant (Figure 1E).  For a subset of the patients (n=22), longitudinal serum 
samples were available.  Three of those patients showed worsening oxygenation during the 
period of collection (room air to nasal-cannula oxygen, nasal-cannula oxygen to high-flow 
oxygen, and room air to mechanical ventilation, respectively).  For all three, markers of NETs 
trended up as oxygenation worsened (Supplemental Figure 1).   All available samples (n=84) 
were included in the subsequent correlation analyses.  In summary, three markers indicative of 
NET remnants are elevated in sera of COVID-19 patients as compared with controls. 
 
Association between NETs and clinical biomarkers.  Given that circulating NETs may be 
drivers of, or form in response to, other blood products, we next asked how the aforementioned 
NET markers compared to several commonly available clinical tests.  Specifically, we assessed 
potential correlations with C-reactive protein, D-dimer, lactate dehydrogenase, absolute 
neutrophil count, and platelet count.  To draw integral comparisons, we limited the analysis of 
clinical laboratory measurements to those performed on the same day as serum used for NET 
assays.  Cell-free DNA demonstrated a strong positive correlation with all of the clinical tests 
other than platelet count (Figure 2A-D).  When we compared the clinical labs with MPO-DNA, 
we detected a strong positive correlation with absolute neutrophil count (Figure 2E), while C-
reactive protein (r=0.10, p=0.44), D-dimer (r=0.05, p=0.72) and lactate dehydrogenase (r=0.17, 
p=0.22) demonstrated positive slopes that were not statistically significant.  Interestingly, Cit-H3 
levels were positively correlated with platelet counts (Figure 2F), but not the other clinical 
laboratory measurements.  All available samples (n=84) were included in the correlation 
analyses of Figure 2.  When only including the first-available sample from each patient (n=50), 
correlations were similar (Supplemental Figure 2).  Approximately half of patients were treated 
with hydroxychloroquine (Table 1).  We did not find a difference in NET markers from samples 
collected on days of hydroxychloroquine administration versus those without (Supplemental 
Figure 3).  In summary, cell-free DNA and to a lesser extent MPO-DNA and Cit-H3 demonstrate 
significant correlations with clinical studies routinely used in the care of COVID-19 patients. 
 
NETs associate with severe disease including mechanical ventilation.  We next 
determined the clinical status associated with each available serum sample.  We compared 
samples from patients with severe COVID-19 (those requiring mechanical ventilation, n=27 
samples) to patients with mild or moderate COVID-19 (oxygen saturation >94% on ambient air, 
n=24 samples).    As compared with patients breathing room air, patients requiring mechanical 
ventilation had significantly higher levels of cell-free DNA (Figure 3A) and MPO-DNA (Figure 
3B), but not Cit-H3 (Figure 3C).  Absolute neutrophil counts were not significantly higher in the 
ventilated patients (Figure 3D).  Taken together, these data suggest a possible relationship 
between level of serum NETs and severity of COVID-19. 
 
COVID-19 sera trigger control neutrophils to release NETs.  If COVID-19 presents a milieu 
favoring NETosis, we reasoned that direct exposure of control neutrophils to patient sera 
(without any additional agonist) would trigger these healthy neutrophils to undergo NETosis.  As 
compared with heterologous control sera, the patient sera robustly promoted NETosis whether 
measured by externalization of DNA (Figure 4A) or release of DNA-bound MPO enzyme 
(Figure 4B).  Immunofluorescence microscopy demonstrated extracellular chromatin structures 
decorated with neutrophil elastase characteristic of NETs (Figure 4C).  In summary, serum 
samples from COVID-19 patients robustly trigger healthy neutrophils to undergo NETosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
Here, we report for the first time elevated levels of serum NETs in many hospitalized patients 
with COVID-19.  We measured three markers commonly used to detect NET remnants in blood 
(cell-free DNA, MPO-DNA, and Cit-H3), and found significant elevations in all three.  We also 
found that COVID-19 sera are potent stimulators of NETosis when added to control neutrophils.  
Taken together, these data provide evidence that COVID-19, at least in hospitalized patients, is 
a pro-NETotic state.  The triggers of NETosis in COVID-19 are potentially myriad and will 
require further investigation.  Possibilities include virus-damaged epithelial cells (13, 29), 
activated platelets (30, 31), activated endothelial cells (32), and inflammatory cytokines such as 
IL-1β (19, 33), IL-8 (34, 35), granulocyte colony stimulating factor (36, 37), and likely others 
(17). 
 
Of the markers we tested, cell-free DNA was most closely aligned with traditional inflammatory 
markers used to track COVID-19 including C-reactive protein, D-dimer, and lactate 
dehydrogenase.  Notably, although cell-free DNA is not a highly specific marker for NETs, it was 
strongly correlated with absolute neutrophil count, as was the more specific marker of NETs, 
MPO-DNA.  Somewhat unexpectedly, Cit-H3 did not correlate well with the other two markers, 
but did associate strongly with platelet levels.  It is believed that the predominant driver of 
histone citrullination (i.e., production of Cit-H3) in NETs is the enzyme peptidlyarginine 
deiminase 4 (PAD4) (38).  However, neutrophils can be triggered to undergo NETosis by a 
variety of stimuli, and in vitro studies demonstrate that not all pathways to NETosis are equally 
reliant on PAD4 activity (39); for example, stimuli that lead to robust reactive oxygen species 
production may be relatively PAD4-independent (40).  The dichotomy between MPO-DNA and 
Cit-H3 levels in the COVID-19 sera tested here potentially suggests that two or more pathways 
to NETosis are active in COVID-19 patients, with the pathway leading to Cit-H3 perhaps having 
some relationship to platelets (41).  It should also be noted that neutrophils are relatively short-
lived cells that may experience cell death through many pathways including apoptosis, necrosis, 
pyroptosis, NETosis, and others.  Markers such as lactate dehydrogenase, cell-free DNA, and 
Cit-H3 may therefore also be produced by neutrophil cell death that is independent of NETosis 
(42, 43).  The activation of other cell death programs, and their relationship to the inflammatory 
storm, certainly warrant further investigation in COVID-19. 
 
NETs were first described in 2004 as a novel pathogen eradication strategy that could function 
as an alternative to phagocytosis (35), but it is now recognized that NETs have double-edged-
sword properties and likely exacerbate (and in some cases even initiate) autoimmune and 
vascular diseases (44).  NETs present and stabilize a variety of oxidant enzymes in the 
extracellular space, including MPO, NADPH oxidase, and nitric oxide synthase (45), while also 
serving as a source of extracellular histones that carry significant cytotoxic potential (46, 47).  In 
light of these toxic cargo, it is not surprising that NETs play a role in a variety of lung diseases 
including cystic fibrosis (where they occlude larger airways) (48), smoking-related lung disease 
(49), and, with particular relevance here, pathogen-induced acute lung injury and ARDS (13, 50, 
51).  NETs have also been very well studied in the setting of cardiovascular disease where they 
infiltrate and propagate inflammation in the vessel wall (52), and, when formed intravascularly, 
occlude arteries (53), veins (54), and microscopic vessels (55).  Early studies of COVID-19 
suggest a high risk of morbid arterial events (56), and one can speculate that the risk of venous 
thrombosis will increasingly reveal itself as more data become available (57). 
 
Severe COVID-19 appears to be defined by neutrophilia, as well as elevations in IL-1β, IL-6, 
and D-dimer (17), the latter suggesting hyperactivity of the coagulation system.  All these 
findings have significant potential for cross-talk with NETs.  NETs are linked to IL-1β (both 
upstream and downstream) in cardiovascular and pulmonary diseases (18-21), including as 
described by our group for venous thrombosis (8).  The same is true for IL-6, either directly (22), 
or perhaps with IL-1β as an intermediary (23).  Of course, as discussed above, examples of 
NETs as drivers of thrombosis are myriad, as intravascular NETosis is responsible for initiation 
and accretion of thrombotic events in arteries, veins, and—particularly pertinent to COVID-19—
the microvasculature, where thrombotic disease can drive end-organ damage in lungs, heart, 
kidneys, and other organs (58, 59).  Mechanistically, NETs, via electrostatic interactions, 
activate the contact pathway of coagulation (60), while also presenting tissue factor to activate 
the intrinsic pathway (61).  Simultaneously, serine proteases in NETs dismantle natural brakes 
on coagulation such as tissue factor pathway inhibitor and antithrombin (62).  Bidirectional 
interplay between NETs and platelets may also be critical for COVID-19-associated 
microvascular thrombosis as has been characterized in a variety of disease models (59, 60). 
 
Of interest, a recent small study performed in China suggested potential efficacy of the 
adenosine-receptor agonist, dipyridamole in severe cases of COVID-19 (63).  Dipyridamole is 
an FDA-approved drug that our group recently discovered to inhibit NET formation by activation 
of adenosine A2A receptors (6).  In the aforementioned trial, patients with COVID-19-associated 
bilateral pneumonia were treated with oral dipyridamole for seven days, in addition to treatment 
with antiviral agents (63).  As compared with controls, dipyridamole-treated patients 
demonstrated improvements in platelet counts and D-dimer levels (63).  Given the urgent need 
for effective treatments of COVID-19, a randomized study to characterize the impact of 
dipyridamole on COVID-19-related NETosis, thrombo-inflammatory storm, and, of course, 
outcomes may be warranted.  Other approaches to combatting NETs have been reviewed (64, 
65), and include the dismantling of already-formed NETs (deoxyribonucleases) and strategies 
that might prevent initiation of NET release, including inhibitors of neutrophil elastase and 
PAD4. 
 
This study is not without limitations including the use of serum samples retrieved from the 
clinical laboratory, rather than samples drawn specifically for research purposes.  Here, it is 
certainly possible that NETs were partially degraded over time, thereby lowering our 
measurements.  It should also be emphasized that it is not clear whether the NET remnants 
described here are drivers of disease severity or a mere consequence of acute inflammation in 
patients.  Indeed, the definitive accounting of COVID-19 pathophysiology and answering 
questions of causality will likely await the development of model systems.  Our hope though is 
that these findings will ignite further research into the role of neutrophil effector functions in the 
complications of COVID-19 (66).  As a first step, future studies should investigate the predictive 
power of circulating NETs in well-phenotyped longitudinal cohorts.  Furthermore, given the 
dichotomy we found here between MPO-DNA and Cit-H3, investigators should be encouraged 
to continue to include diverse markers of NETosis in future studies.  As we await definitive 
antiviral and immunologic solutions to the current pandemic, we posit that anti-neutrophil 
therapies may be part of a personalized strategy for some individuals affected by COVID-19 
who are at risk for progression to respiratory failure. 
 
 
 
 
 
 
 
 
 
 
METHODS 
Human samples.  Serum samples from 50 hospitalized COVID-19 patients (84 total samples) 
were used in this study.  Blood was collected into serum separator tubes containing clot 
activator and serum separator gel by a trained hospital phlebotomist.  After completion of 
biochemical testing ordered by the clinician, the remaining serum was stored at 4°C for up to 48 
hours before it was deemed “discarded” and released to the research laboratory.  Serum 
samples were immediately divided into small aliquots and stored at -80°C until the time of 
testing.  All 50 patients had a confirmed COVID-19 diagnosis based on FDA-approved RNA 
testing.  This study complied with all relevant ethical regulations, and was approved by the 
University of Michigan Institutional Review Board (HUM00179409), which waived the 
requirement for informed consent given the discarded nature of the samples.  Healthy 
volunteers were recruited through a posted flyer; exclusion criteria for these controls included 
history of a systemic autoimmune disease, active infection, and pregnancy.  For preparation of 
control serum, blood was collected into serum separator tubes containing clot activator and 
serum separator gel by a trained hospital phlebotomist.  Samples were centrifuged at 
approximately 2000 xg, similar to the clinical samples.  These serum samples were divided into 
small aliquots and stored at -80°C until the time of testing. 
 
Quantification of cell-free DNA.  Cell-free DNA was quantified in sera using the Quant-iT 
PicoGreen dsDNA Assay Kit (Invitrogen, P11496) according to the manufacturer’s instructions. 
 
Quantification of citrullinated histone H3.  Citrullinated histone H3 was quantified in sera 
using the Citrullinated Histone H3 (Clone 11D3) ELISA Kit (Cayman, 501620) according to the 
manufacturer’s instructions. 
 
Quantification of MPO-DNA complexes.  MPO-DNA complexes were quantified similarly to 
what has been previously described (67).  This protocol used several reagents from the Cell 
Death Detection ELISA kit (Roche).  First, a high-binding EIA/RIA 96-well plate (Costar) was 
coated overnight at 4ºC with anti-human MPO antibody (Bio-Rad 0400-0002), diluted to a 
concentration of 1 µg/ml in coating buffer (Cell Death kit).  The plate was washed two times with 
wash buffer (0.05% Tween 20 in PBS), and then blocked with 4% bovine serum albumin in PBS 
(supplemented with 0.05% Tween 20) for 2 hours at room temperature.  The plate was again 
washed five times, before incubating for 90 minutes at room temperature with 10% serum or 
plasma in the aforementioned blocking buffer (without Tween 20).  The plate was washed five 
times, and then incubated for 90 minutes at room temperature with 10x anti-DNA antibody 
(HRP-conjugated; from the Cell Death kit) diluted 1:100 in blocking buffer.  After five more 
washes, the plate was developed with 3,3',5,5'-Tetramethylbenzidine (TMB) substrate 
(Invitrogen) followed by a 2N sulfuric acid stop solution.  Absorbance was measured at a 
wavelength of 450 nm using a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek).  Data were 
normalized to in vitro-prepared NET standards included on every plate, which were quantified 
based on their DNA content. 
 
Human neutrophil purification.  For neutrophil preparation, blood from healthy volunteers was 
collected into sodium citrate tubes by standard phlebotomy techniques.  The anticoagulated 
blood was then fractionated by density-gradient centrifugation using Ficoll-Paque Plus (GE 
Healthcare).  Neutrophils were further purified by dextran sedimentation of the red blood cell 
layer, before lysing residual red blood cells with 0.2% sodium chloride.  Neutrophil preparations 
were at least 95% pure as confirmed by nuclear morphology. 
 
NETosis assay (SYTOX Green).  A cell-impermeant dye SYTOX Green (Thermo Fisher) was 
used to measure NETosis.  Briefly, purified neutrophils were resuspended in 1x PBS (Gibco). 
1x105 neutrophils were seeded into each well of a 0.001% poly-L-lysine (Sigma)-coated 96-well 
black clear-bottom non-tissue culture plate (Costar), and were allowed to adhere for 20 minutes 
at 37°C and 5% CO2.  PBS was gently removed and control/patient serum (diluted to 10% in 
RPMI culture media supplemented with L-glutamine) was carefully added without disrupting 
adherent cells.  SYTOX Green was added at the same time to a final concentration of 500 nM.  
All treatments were done in triplicate.  Cells were allowed to undergo NETosis for 4 hours.  
Culture media was then gently removed and fresh 1x PBS was added to each well.  
Fluorescence was quantified at excitation and emission wavelengths of 504 nm and 523 nm, 
respectively, using a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek).  Data were collected 
using the area-scan setting of the plate reader.  
 
NETosis assay (NET-associated MPO).  Purified neutrophils were resuspended in RPMI 
media (Gibco) supplemented with 0.5% bovine serum albumin (BSA, Sigma), 0.5% heat-
inactivated fetal bovine serum (FBS, Gibco) and L-glutamine.  Neutrophils (1 x 105 /well) were 
cultured in a 96-well tissue culture plate (Costar) in the presence of either patient or control 
serum, diluted to a final concentration of 10%.  Plates were incubated for 3 hours at 37°C and 
5% CO2.  To collect NET-associated MPO, the culture media was discarded (to remove any 
soluble MPO) and replaced with 100 µL of PBS supplemented with 5 U/ml Micrococcal nuclease 
(Thermo Fisher).  After 10 minutes at 37ºC, digestion of NETs was stopped with 10 mM EDTA.  
Supernatants were transferred to a v-shaped 96 well plate, and centrifuged at 400xg for 5 
minutes to remove debris.  Supernatants were then transferred into a new flat-bottom 96-well 
plate.  To quantify MPO activity, an equal volume of 3,3',5,5'-tetramethylbenzidine (TMB) 
substrate (Thermo Fisher) was added to each well.  After 10 minutes of incubation in the dark, 
the reaction was stopped by the 2N sulfuric acid solution.  Absorbance was measured at 450 
nm using a Cytation 5 Cell Imaging Multi-Mode Reader. 
 
NETosis assay (microscopy).  For immunofluorescence microscopy, 1x105 neutrophils were 
seeded onto coverslips coated with 0.001% poly-L-lysine (Sigma) and cultured as for the above 
assays.  Samples were then fixed with 4% paraformaldehyde for 10 minutes at room 
temperature, followed by blocking with 10% FBS in PBS.  The primary antibody was against 
neutrophil elastase (Abcam 21595, diluted 1:100), and the FITC-conjugated secondary antibody 
was from SouthernBiotech (4052-02, diluted 1:250).  DNA was stained with Hoechst 33342 
(Invitrogen).  Images were collected with a Cytation 5 Cell Imaging Multi-Mode Reader. 
 
Statistical analysis.  Normally-distributed data were analyzed by two-sided t test and skewed 
data were analyzed by Mann-Whitney test.  Data analysis was with GraphPad Prism software 
version 8.  Correlations were tested by Pearson’s or Spearman’s correlation coefficient as 
indicated.  Statistical significance was defined as p<0.05 unless stated otherwise. 
 
Study approval.  The study was approved by the University of Michigan Institutional Review 
Board (HUM00179409). 
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Figure 1:  Detection of NETs in sera of COVID-19 patients.  Sera from COVID-19 patients 
(n=50) and healthy controls (n=30) were assessed for cell-free DNA (A), myeloperoxidase 
(MPO)-DNA complexes (B), or citrullinated histone H3 (C).  COVID-19 samples were compared 
to controls by Mann-Whitney test; ***p<0.001, ****p<0.0001.  For the COVID-19 samples, 
correlation of cell-free DNA with MPO-DNA (D) and citrullinated histone H3 (E) were assessed.  
Spearman’s correlation coefficients were calculated and are shown in the panels. 
 
 
 
 
 
 
 
 
 
 
  
Figure 2:  Association between NETs and clinical biomarkers in all available serum 
samples.  Cell-free DNA was compared to clinical laboratory results (when available on the 
same day), and correlation coefficients were calculated for C-reactive protein (A, n=64), D-
dimer (B, n=56), lactate dehydrogenase (C, n=55), and absolute neutrophil count (D, n=69).  In 
panel E (n=69), MPO-DNA was compared to absolute neutrophils count and in F (n=81), 
citrullinated histone H3 was compared to platelet count.  The results of other relevant 
comparisons are discussed in the text.  Pearson’s correlation coefficients were calculated and 
are shown in the panels. 
 
 
  
Figure 3:  Levels of NETs associate with mechanical ventilation in all available serum 
samples.  Serum samples were grouped by clinical status (room air versus mechanical 
ventilation), and analyzed for cell-free DNA (A, n=51), myeloxperoxidase (MPO)-DNA 
complexes (B, n=51), citrullinated histone H3 (C, n=51), and absolute neutrophil count (D, 
n=42).  Groups were compared by Mann-Whitney test; ****p<0.0001, *p<0.05.  For panel D, the 
p value was 0.08. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4:  COVID-19 sera trigger control neutrophils to release NETs.  COVID-19 samples 
(for which sufficient sera were available) were tested for their ability to trigger neutrophils 
isolated from healthy controls to undergo NETosis.  A, NETosis was quantified using the cell-
impermeant dye SYTOX Green as described in Methods (n=27 COVID-19 samples and n=20 
controls).  Fluorescence intensity (excitation/emission 504/523) is shown on the y-axis.  Bars 
demonstrate mean and standard deviation while each data point represents a unique 
patient/control; ***p<0.001 by t test.  B, In an independent set of experiments, NETosis was 
quantified as nuclease-liberated myeloperoxidase (MPO) activity (n=27 COVID-19 samples and 
n=17 controls).  Absorbance at 450 nm is shown on the y-axis after subtracting background 
from untreated cells.  Bars demonstrate mean and standard deviation while each data point 
represents a unique patient/control; **p<0.01 by t test.  C, Representative image of control 
neutrophils cultured with 10% heterologous control serum (upper) or COVID-19 serum (lower).  
Neutrophil elastase is stained green and DNA is stained blue.  Scale bar=100 microns.  The 
yellow arrows highlight some examples of NET strands. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1:  COVID-19 patient characteristics 
Demographics   
Number 50  
Age (years)*  61 ± 15 (29-91) 
Hospital day** ‡ 3.7 ± 4.1 (1-25) 
Female 17 (34%) 
White/Caucasian 19 (38%) 
Black/African-American 29 (18%) 
Comorbidities   
Diabetes 16 (32%) 
Heart disease 12 (24%) 
Renal disease 16 (32%) 
Lung disease 17 (34%) 
Autoimmune 4 (8%) 
Cancer 10 (20%) 
History of stroke 3 (6%) 
Obesity 23 (46%) 
Hypertension 37 (74%) 
Immune deficiency 3 (6%) 
History of smoking 18 (36%) 
Medications‡   
Hydroxychloroquine 24 (48%) 
Anti-IL6 receptor 2 (4%) 
ACE inhibitor 1 (2%) 
Angiotensin receptor blocker 0 (0%) 
Antibiotic 22 (44%) 
Antiviral 0 (0%) 
Respiratory status‡   
Mechanical ventilation 16 (32%) 
High-flow oxygen 2 (4%) 
Nasal-cannula oxygen 17 (34%) 
Room air 15 (30%) 
* Mean ± standard deviation 
** Median = 2 
‡ At time of first sample available for testing 
 
